Case Study: De‑Risking Drug Substance Development Through Route and Solid‑State Optimisation

A UK-based oncology biotech partnered with Arcinova to overcome critical drug substance development challenges that were threatening programme progression.

This case study highlights how our route optimisation and solid-state expertise transformed an unstable, low-yielding API process into a robust, scalable kilogram-scale manufacturing route.

Download the case study to discover how Arcinova delivered a stable solid form, achieved a greater than two-fold increase in yield, and established a GMP-suitable route to support future clinical development.